FGF2 and Miyoshi myopathy: A recent clinical study involving MM patients (GIMEMA-MM0305 NCT01063179) has shown that high levels of VEGF and FGF-2 were associated with an unfavorable prognosis, supporting the notion that VEGF plays an important role in MM progression and suggesting that angiogenic factors may be used as non-invasive prognostic biomarkers in MM [54].